Illana Gozes
Professor Emerita
Sagol School of Neuroscience
Tel Aviv University;The Adams Super Center for Brain Studies, Tel Aviv University;Elton Laboratory for Molecular Neuroendocrinology, Tel Aviv University;Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University
关注
立即认领
分享
关注
立即认领
分享
基本信息
浏览量:32
职业迁徙
个人简介
Our research is characterized by a multi-level approach to the study of brain function, behavior, memory and drug discovery, from molecules to cures. Targeting autism, schizophrenia as well as Alzheimer’s disease and related neurodegeneration and utilizing a multidisciplinary approach, our group investigates different aspects of neuronal plasticity and nerve cell protection, at the molecular, cellular and system level.
A major focus in the laboratory is on nerve structure and transport mechanisms. We have discovered novel families of proteins associated with cross talk among nerve cells and their support cells, including activity-dependent neurotrophic factor (ADNF) and activity-dependent neuroprotetive proteins (ADNPs, with ADNP being a major gene mutated in autism). Small ADNF and ADNP derivatives are in clinical development. The lead compound, davunetide is planned for an advanced Phase II clinical trial with the biotech industry.
Davunetide has previously shown efficacy in several Phase II clinical trials (i.e. in patients suffering from mild cognitive impairment, preceding Alzheimer's disease and in schizophrenia patients, protecting activities of daily living).
A major focus in the laboratory is on nerve structure and transport mechanisms. We have discovered novel families of proteins associated with cross talk among nerve cells and their support cells, including activity-dependent neurotrophic factor (ADNF) and activity-dependent neuroprotetive proteins (ADNPs, with ADNP being a major gene mutated in autism). Small ADNF and ADNP derivatives are in clinical development. The lead compound, davunetide is planned for an advanced Phase II clinical trial with the biotech industry.
Davunetide has previously shown efficacy in several Phase II clinical trials (i.e. in patients suffering from mild cognitive impairment, preceding Alzheimer's disease and in schizophrenia patients, protecting activities of daily living).
研究兴趣
论文共 606 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Journal of Molecular Neuroscienceno. 1 (2024): 1-14
American journal of medical genetics. Part Ano. 5 (2024): e63539-e63539
JOURNAL OF NEUROCHEMISTRY (2023): 149-149
引用0浏览0引用
0
0
PLoS biologyno. 5 (2023): e3002082-e3002082
European Journal of Neuroscience (2023)
JOURNAL OF THE NEUROLOGICAL SCIENCES (2023): 121948
IUPHAR/BPS guide to pharmacology CITEno. 1 (2023)
引用1浏览0引用
1
0
Translational Psychiatryno. 1 (2023): 1-10
引用0浏览0WOSNATURE引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn